Navigation Links
Covis Pharmaceuticals, Inc Named US Distributor For Five Additional Products
Date:4/5/2013

CARY, N.C., April 5, 2013 /PRNewswire/ -- Covis Pharmaceuticals, Inc. announced an agreement today to distribute Nilandron® (nilutamide), Plaquenil® (hydroxychloroquine), Rilutek® (riluzole), Uroxatral® (alfuzosin hydrochloride) and Kayexalate® (sodium polystyrene sulfate) in the United States.

The products cover a broad array of treatments and disease states:  Nilandron is used to treat prostate cancer; Plaquenil is an anti-malarial drug; Rilutek treats amyotrophic lateral sclerosis; Uroxatral is used to treat Benign Prostatic Hyperplasia (BPH); and, Kayexalate is prescribed to remove dangerously high levels of potassium in the blood.  With the addition of these products, Covis Pharmaceuticals, Inc. will be distributing 11 brands in the United States.  As part of their mission to ensure availability and access to all products, Covis will continue to offer a patient assistance program

"This agreement underscores our commitment to provide patients with a continuous supply of safe and efficacious therapeutic solutions," said Bill Collins , Chief-Executive-Officer of Covis.  "These additional products will allow Covis to broaden our portfolio with consistent, top quality branded pharmaceuticals."  

The company's current product portfolio includes Lanoxin® (digoxin) Tablets, Lanoxin® (digoxin) IV, Parnate® (tranylcypromine sulfate tablets), Zantac® (ranitidine hydrochloride) Injection, Fortaz® (ceftazidime for injection) and Zinacef® (cefuroxime for injection).  For full prescribing information on these Covis products, including boxed warnings for Parnate®, please visit www.covispharma.com or contact the Company at 919-535-3049.  For full prescribing information on Nilandron Tablets, Plaquenil Tablets, Rilutek Tablets, Uroxatral Tablets, and Kayexalate Powder, including boxed warnings for Nilandron and Plaquenil, please visit http://dailymed.nlm.nih.gov.

Fortaz®, Zinacef®, Lanoxin®, and Parnate® are registered trademarks of the GlaxoSmithKline group of companies. Zantac® is a registered trademark of Boehringer Ingelheim Pharmaceuticals, Inc., used under license.

About Covis Pharmaceuticals, Inc.   
Covis Pharmaceuticals is a specialty pharmaceutical distributor dedicated to improving the lives of people with life-threatening conditions and chronic illnesses. It is our mission to provide our customers with a continuous supply of safe and efficacious therapeutic solutions. The Website is: www.covispharma.com.


'/>"/>
SOURCE Covis Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Almost 50 Percent of the Glaucoma Patient Population Remains Untreated, Signifying a Vast Market for Glaucoma Pharmaceuticals, Finds Frost & Sullivan
2. Provectus Pharmaceuticals, Inc.s Investor Presentation Now Available for On-demand Viewing at RetailInvestorConferences.com
3. Keryx Biopharmaceuticals, Inc. To Host Conference Call on First Quarter 2012 Financial Results
4. Keryx Biopharmaceuticals, Inc. Announces First Quarter 2012 Financial Results
5. Auxilium Pharmaceuticals, Inc. to Present At The BofAML 2012 Health Care Conference
6. Depomed Announces Receipt of $1 million Milestone Payment From Ironwood Pharmaceuticals, Inc.
7. Auxilium Pharmaceuticals, Inc. and FCB I LLC Announce the Issuance of Composition of Matter Patent Covering Testim
8. Auxilium Pharmaceuticals, Inc. Raises Revenue Guidance And Reduces Net Loss Guidance For 2012
9. Auxilium Pharmaceuticals, Inc. to Present at the Goldman Sachs Global Healthcare Conference 2012
10. Hybrid Fuels, Inc. Announces Name Change to Nouveau Life Pharmaceuticals, Inc.
11. Debiopharm and Ascepion Pharmaceuticals, Inc. Announce an Exclusive License Agreement for the Development and Commercialisation of the Dual-Targeting Kinase Inhibitor, ASP-08126 (Debio 1144), for the Treatment of Oncology Diseases
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/20/2017)... Seal Shield LLC ( Jacksonville, FL ... device management and disinfection, the ElectroClave™, to the exhibit ... Orlando, Fla. from February 20-23, ... become commonplace in today,s healthcare landscape, but with this ... including the disinfection and tracking of these devices.  The ...
(Date:2/20/2017)... 20, 2017  There has been a paradigm shift ... across sub-Saharan Africa, which in turn is driving the ... more Western lifestyle diseases such as cardiovascular disease (CVD), ... and parasitic illness, will present the pharmaceutical industry in ... of $40.8 billion in 2019. "An increase ...
(Date:2/20/2017)... FRANCISCO , February 20, 2017 ... management market  is anticipated to reach USD 1.4 ... by Grand View Research, Inc. Constant evaluation of ... management is expected to drive growth in this ... investment for development of novel and improved shunts ...
Breaking Medicine Technology:
(Date:2/20/2017)... , ... February 20, 2017 , ... ... check-in, a cloud-based self-service technology that runs on the Posiflex XT-series of touch ... 1076 during HIMSS17 in Orlando, Florida. The terminal provider Posiflex is ...
(Date:2/20/2017)... ... February 20, 2017 , ... Sensogram Technologies Inc., the ... a visit this week at HIMSS 2017 Conference & Exhibition. The event brings ... Sensogram will be featured in the conference’s Connected Health Experience section, an area ...
(Date:2/20/2017)... Houston, TX (PRWEB) , ... February 20, 2017 ... ... he is now offering a full range of emergency dental care at his ... teeth and gums. When patients experience dental emergencies, they are at risk for ...
(Date:2/20/2017)... ... February 20, 2017 , ... Today, Illuma Care ... partners, announced during the 2017 Annual HIMSS Conference & Exhibition in ... diabetic patients and integrating eye care into mainstream healthcare delivery is powered by ...
(Date:2/19/2017)... ... 19, 2017 , ... Braun Industries will be participating as an exhibitor at ... take place February 23-25, 2017 at the Calvin L. Rampton Salt Palace Convention Center ... new ambulances on display. , “JEMS is a leader in EMS ...
Breaking Medicine News(10 mins):